The Effect of Beta-glucan in Non-Small Cell Lung Cancer

Launched by UNIVERSITY OF LOUISVILLE · May 20, 2008

Keywords

ClinConnect Summary

This clinical trial is investigating how a substance called beta-glucan can impact the immune system in patients diagnosed with non-small cell lung cancer (NSCLC). The goal is to understand if beta-glucan can help support the immune response against the cancer. The trial is currently recruiting participants aged between 65 and 74, and it is open to all genders. To be eligible, individuals must have a confirmed diagnosis of NSCLC, should not have received any cancer treatment in the past six months, and must be able to swallow pills. Additionally, they should have a certain level of health and be able to understand and agree to the study requirements.

Participants in this trial can expect to take beta-glucan pills and undergo regular check-ups to monitor their health and any changes in their cancer. It's important to note that individuals with a history of severe allergic reactions to beta-glucan, those currently on certain immune-suppressing medications, or those with serious health issues may not be eligible to join. Overall, this study aims to explore a potential new way to help the immune system fight non-small cell lung cancer, and participants will play a vital role in advancing our understanding of this treatment.

Gender

ALL

Eligibility criteria

• AIM 2:
• Inclusion Criteria:
• • suspected or definitive diagnosis of non-small cell lung cancer (NSCLC)
• • treatment naive or no treatment within 6 months prior to enrollment
• • able to swallow pills
• • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3
• • absolute neutrophil count (ANC) at least 1500/microl
• • able to understand and willing to sign a written informed consent document
• Exclusion Criteria:
• • history of hypersensitivity reactions attributed to beta-glucan
• • currently receiving continuous corticosteroids or other ongoing immunosuppressive therapy
• • presence of an uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• AIM 3:
• Inclusion Criteria:
• • resectable non-small cell lung cancer (NSCLC), as determined by a thoracic surgeon
• • treatment naive
• • able to swallow pills
• • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
• • must be an operative candidate
• • absolute neutrophil count (ANC) at least 1500/microl
• • able to understand and willing to sign a written informed consent document
• Exclusion Criteria:
• • history of hypersensitivity reactions attributed to beta-glucan
• • currently receiving continuous corticosteroids or other ongoing immunosuppressive therapy
• • presence of an uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements